Unlocking the mystery of tau for treatment of neurodegenerative diseases

Unlocking the mystery of tau for treatment of neurodegenerative diseases
Under normal physiological conditions, FUS and SFPQ interact in the nucleus of nerve cells and regulate the alternative splicing of MAPT by excising exon 10. When this functional machinery is impaired, the splicing ratio of MAPT exon 10+/exon 10- is increased, which in turn results in an increased 4R-Tau/3R-Tau ratio. The findings of Dr Ishigaki’s team suggest the presence of a pathophysiological link between FUS/SFPQ interaction and the regulation of 4R-Tau/3R-Tau isoforms, which is involved in the pathogenesis of FTLD spectrum diseases. Credit: Shinsuke Ishigaki

Frontotemporal lobar degeneration (FTLD) is a type of dementia that appears earlier in life than Alzheimer’s disease (AD). Both FTLD and AD, along with several other neurodegenerative diseases, are marked by the appearance and…

Read more…